Table 1.
Revised Central Nervous System Penetration-Effectiveness Ranking
| Antiretroviral Drug Class | 4 | 3 | 2 | 1 |
|---|---|---|---|---|
| Nucleoside analogue reverse transcriptase inhibitors | Zidovudine | Abacavir | Didanosine | Tenofovir |
| Emtricitabine | Lamivudine | Zalcitabine | ||
| Stavudine | ||||
|
| ||||
| Nonnucleoside analogue reverse transcriptase inhibitors | Nevirapine | Delavirdine | Etravirine | |
| Efavirenz | ||||
|
| ||||
| Protease inhibitors | Indinavir/ritonavir | Darunavir/ritonavir | Atazanavir | Nelfinavir |
| Fosamprenavir/ritonavir | Atazanavir/ritonavir | Ritonavir | ||
| Indinavir | Fosamprenavir | Saquinavir | ||
| Lopinavir/ritonavir | Saquinavir/ritonavir | |||
| Tipranavir/ritonavir | ||||
|
| ||||
| Entry/fusion inhibitors | Maraviroc | Enfuvirtide | ||
|
| ||||
| Integrase strand transfer inhibitors | Raltegravir | |||
Note: Larger numbers reflect estimates of better penetration or effectiveness in the central nervous system (eg, a ranking of 4 indicates the best penetration or effectiveness). Based on data from Abstract 172.